UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 955

Sortiert nach

An Overview of PARP Inhibitors for the Treatment of Breast Cancer

Targeted oncology, 2021-05, Vol.16 (3), p.255-282

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

CA: a cancer journal for clinicians, 2017-07, Vol.67 (4), p.290-303

2017

Link zum Volltext

Verfügbarkeit prüfen

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

Cancer cell, 2014-11, Vol.26 (5), p.623-637

2014

Link zum Volltext

Verfügbarkeit prüfen

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2019-05, Vol.380 (20), p.1929-1940

2019

Link zum Volltext

Verfügbarkeit prüfen

Palbociclib and Letrozole in Advanced Breast Cancer

The New England journal of medicine, 2016-11, Vol.375 (20), p.1925-1936

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

International journal of cancer, 2020-10, Vol.147 (8), p.2190-2198

2020

Link zum Volltext

Verfügbarkeit prüfen

Management of Cancer Cachexia: ASCO Guideline

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2438-2453

2020

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

JNCI : Journal of the National Cancer Institute, 2021-08, Vol.113 (8), p.1005-1016

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2535-2541

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Journal of clinical oncology, 2017-12, Vol.35 (36), p.4035-4041

2017

Link zum Volltext

Verfügbarkeit prüfen

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Link zum Volltext

Verfügbarkeit prüfen

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (32), p.4286-4293

2011

Link zum Volltext

Verfügbarkeit prüfen

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2585-2592

2012

Link zum Volltext

Verfügbarkeit prüfen

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Link zum Volltext

Verfügbarkeit prüfen

Immune microenvironments in solid tumors: new targets for therapy

Genes & development, 2011-12, Vol.25 (24), p.2559-2572

2011

Link zum Volltext

Verfügbarkeit prüfen

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data

Clinical breast cancer, 2016-02, Vol.16 (1), p.8-17

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice

Breast cancer research : BCR, 2021-03, Vol.23 (1), p.37-37, Article 37

2021

Link zum Volltext

Verfügbarkeit prüfen

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Breast (Edinburgh), 2022-12, Vol.66, p.169-177

2022

Link zum Volltext

Verfügbarkeit prüfen

Leukocyte composition of human breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2012-02, Vol.109 (8), p.2796-2801

2012

Link zum Volltext

Verfügbarkeit prüfen

The cancer glycocalyx mechanically primes integrin-mediated growth and survival

Nature (London), 2014-07, Vol.511 (7509), p.319-325

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3234-3241

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 955

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(935)
Mit Volltextzugriff
(884)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(439)
Life Sciences & Biomedicine
(433)
Oncology
(387)
Humans
(368)
Female
(309)
Breast Cancer
(229)
Breast Neoplasms - Drug Therapy
(206)
Middle Aged
(168)
Adult
(146)
Breast Neoplasms - Pathology
(144)
Aged
(140)
Chemotherapy
(114)
Tumors
(104)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(99)
Cancer Therapies
(93)
Metastasis
(88)
Patients
(88)
Cancer
(80)
Cancer Research
(76)
Treatment Outcome
(74)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(278)
Cancer Research
(164)
Breast Cancer Research And Treatment
(58)
Clinical Cancer Research
(36)
Clinical Advances In Hematology & Oncology
(30)
Breast
(27)
The Oncologist
(24)
The New England Journal Of Medicine
(21)
Clinical Breast Cancer
(18)
Npj Breast Cancer
(16)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

An Overview of PARP Inhibitors for the Treatment of Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

Palbociclib and Letrozole in Advanced Breast Cancer

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies

Management of Cancer Cachexia: ASCO Guideline

Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Immune microenvironments in solid tumors: new targets for therapy

Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Leukocyte composition of human breast cancer

The cancer glycocalyx mechanically primes integrin-mediated growth and survival

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2

Suchergebnisse filtern